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Abstract
Background: HIV infected patients have an increased susceptibility to liver disease due to Hepatitis B Virus (HBV), Hepatitis
C Virus (HCV), alcoholic, and non-alcoholic steatohepatitis. Clinically, this results in limited options for antiretroviral therapy
and accelerated rates of liver disease, causing liver disease to be the second leading cause of death for HIV infected patients.
The mechanisms causing this propensity for liver dysfunction during HIV remains unknown.
Methodology/Principal Findings: We demonstrate that HIV and/or the HIV glycoprotein gp120 ligation of CXCR4 on
hepatocytes selectively up-regulates TRAIL R2 expression and confers an acquired sensitivity to TRAIL mediated apoptosis
which is mediated by JNK II, but not p38 nor G-proteins.
Conclusions/Significance: These findings suggest that HIV infection renders hepatocytes more susceptible to liver injury
during disease states associated with enhanced TRAIL production such as HBV, HCV, or steatohepatitis.
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Introduction
Liver disease has become the second most common cause of
death of HIV infected patients [1], and the risk of liver related
death increases with progressive HIV associated immunodeficien-
cy [2]. This observation allows for the possibility that the
pathogenic mechanisms which promote T cell depletion may also
promote liver injury.
In HIV infected patients, liver disease occurs most commonly
from Hepatitis C Virus (HCV) co-infection, active Hepatitis B
Virus (HBV) infection, non-alcoholic steatohepatitis (NASH) [3],
as well as alcohol associated steatohepatitis.
Both HIV associated T cell depletion as well as liver injury are
regulated, at least in part, by disordered apoptosis. In particular, in
both circumstances, the apoptosis inducing ligand TRAIL (TNF
related apoptosis inducing ligand) as well as its cognate receptors
have been implicated. TRAIL exerts apoptotic effects by binding
to and signaling either TRAIL Receptor 1 and/or TRAIL
Receptor 2 expressed on the surface of target cells. Each of HIV,
HBV, and HCV alter the sensitivity of cells they infect by
modulating expression of these receptors [4–6]. Consequently,
diseases caused by each of these viruses are thought to be
mediated, in part, by altered TRAIL: TRAIL receptor interac-
tions. Moreover, in animal models, interrupting TRAIL: TRAIL
receptor signaling ameliorates CD4 T cell depletion of HIV
infected PBL-NOD-SCID mice [7], acute liver injury following
HBV transfection [8] and steatohepatitis following acute viral
infection and alcohol use [9].
It remains unknown how the HIV infection accelerates the
disease course of HCV infection compared to mono-HCV
infection. While it has been suggested that the immunodeficiency
associated with HIV infection may be the reason HCV progresses
more rapidly, two lines of evidence suggest this may not be the
case: first, HCV progression is faster in HIV infected patients with
normal immune function [10,11] and second, the incidence and
progression of other chronic infections, for example, Helicobacter
pylori is no faster in HIV infected individuals [12].
Based upon the combined observations that 1) HCV progres-
sion is faster in HIV co-infection; 2) this effect is not necessarily
solely due to immunodeficiency; and 3) TRAIL dysregulation
characterizes both HIV disease and HCV liver injury, we
hypothesized that the ability of HIV to modulate TRAIL signaling
in T cells might also occur in hepatocytes. We therefore tested
whether HIV particles or HIV proteins altered either TRAIL
receptor expression or TRAIL sensitivity of the human hepatocyte
cells, Huh7.
Materials and Methods
Chemicals and Reagents
Dulbecco’s modification of Eagle’s medium (DMEM) (Media-
tech Inc., Manassas, VA). Fetal bovine serum (FBS) (Atlanta
Biologicals Inc., Lawrenceville, GA). JNK II inhibitor, Pertusis
toxin (PT), SB 203580 (Calbiochem and, San Diego, CA).
Recombinant superkiller TRAIL(skTRAIL) (Alexis Biochemicals,
San Diego, CA). Recombinant HIV-1 IIIB envelope glycoprotein
120 (gp120) and recombinant human T- cell receptor sCD4
(Immuno Diagnostics Inc., Woburn, MA). Bovine serum albumin
(BSA) (Sigma Chemical Co, St. Louis, MO), anti-actin and anti-
tubulin antibodies (Molecular Probes, Carlsbad, CA). AMD3100
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town, MD). Antibodies to TRAIL R1, R2, R3, R4 for flow
cytometry (BD Bioscience, San Diego, CA) and TRAIL R2 for
Western blot (Capralogics Inc., Hardwick, MA), active caspase-3
(BD Biosciences). The MTS, CytoTox96 non-radioactive cyto-
toxicity assay kit (Promega, Madison, WI).
Cell Viability
The human hepatocyte cell line Huh7 (a kind gift from Dr. G.
Gores, Mayo Clinic, Rochester, MN) were cultured at 37uC
DMEM with 10% FBS and 10,000 mg/ml penicillin/streptomycin,
and 200 mM glutamine. The Huh7 cells were plated at a density of
0.1610
5 cells/well in 96-well plates in a final media volume of
200 mL. Cells were pre-incubated with either AMD3100 (10 mM),
Pertussis toxin (1 mg/ml), JNK II inhibitor (400 nM), or SB203580
(8 mM), a p38inhibitor for one hour at 37 uC. Then, 5 mg/mL HIV
glycoprotein 120 (HIV gp120) IIIB or purified X4 HIV IIIb was
added for six hours followed by 100 ng/mL of skTRAIL for twelve
hours. Cell viability was assessed by using 20 mL of the
methanethiosulfonate reagent (MTS) by measuring absorption at
490 nm using spectrophotometric plate reader (EL800, Bio-tek
instruments Inc., Winooski, VT). The mean viability was calculated
and the results were expressed as percentage (%) of MTS reduction.
Western Blots
Huh7 cells (4610
5) were treated with 10 mg gp120 for 0–
3 hours and lysed in lysis buffer (20 mM Tris, pH 7.5, 150 mM
NaCl, 2 mM EDTA, 0.1% Triton-X100, 2 mg/ml aprotinin,
5 mg/ml leupeptin, 1 mM PMSF and 1 mM Saponin) on ice. 50 mg
of protein was resolved on a 15% sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) gel and electrotransferred to poly-
vinylidene fluoride (PVDF) membranes (Millipore Corporation,
Bedford, MA). Membranes were blocked with 5% nonfat milk in
TBST [Tris base (10 mM), NaCl (150 mM), Tween (0.1%),
pH 7.5] for two hours at room temperature and probed with goat
anti TRAIL R2 (1:1000) antibodies overnight at 4uC. Actin
(Sigma, St. Louis, MO) was used as a loading control and intensity
was measured using EL Logic 2200 imaging software system.
Flow Cytometry
Huh7 cells (4610
5) were harvested, washed in cold PBS, and
fixed in 2% paraformaldehyde overnight at 4uC. Cells were
permeabilized with 0.1% NP-40 for 15 minutes (active caspase-3)
on ice, blocked with 2% BSA/PBS and stained with phycoerythrin
(PE) conjugated anti human anti TRAIL R1, R2, R3, R4 mAb
(1:40) or rabbit polyclonal anti-active caspase-3 antibodies (1:40)
or isotype control (Abcam Inc., Cambridge, MA) for one hour on
ice, and analyzed by flow cytometry (FACScan flow cytometer,
BD Biosciences, San Diego, CA).
Statistical Analysis
All results were expressed as the mean6standard deviation (SD)
and repeated at least three times as indicated in the figures.
Statistical comparisons were made by student’s t test employed to
calculate the significance between the paired observations. A p
value of ,0.05 was used as the level of significance [13].
Results
HIV induces hepatocytes to become TRAIL sensitive
In order to determine whether HIV alters the regulation of
TRAIL sensitivity in hepatocytes, concentrated purified whole live
HIV IIIb was used as a clinically relevant source of HIV gp120.
Since Huh7 cells express the HIV receptor CXCR4, cells were pre-
incubated or not with the CXCR4 receptor decoy AMD3100 and
then treated with HIV IIIb. After six hours, skTRAIL was added,
and the following day the cells were fixed, permeabilized, stained
with antibodies that recognize the active form of caspase-3, and
analyzed by flow cytometry. Untreated hepatocytes have sponta-
neous levels of apoptosis of ,5%, while the addition of TRAIL
increased apoptosis only minimally, confirming the relative
resistance of these cells to TRAIL. In addition, and consistent with
prior observations [14,15], treatment with HIV IIIb causes 25% of
human hepatocytes to directly undergo apoptosis. In contrast,
treatment with HIV IIIb followed by TRAIL causes 34% apoptosis
(p,0.05), arguing that HIV sensitizes cells to the pro-apoptotic
effects of TRAIL. AMD3100 pre-treatment blocked both the direct
HIV mediated death as well as the TRAIL induced death (p,.005),
demonstrating that HIV IIIb mediated TRAIL sensitivity in human
hepatocytes occurs via HIV gp120 binding to the CXCR4 co-
receptor (Figure 1). Taken together, this data suggests that HIV
gp120 binds to CXCR4 on the surface of a human hepatocyte, and
signals the cell to become sensitive to TRAIL mediated apoptosis.
HIV gp120 induces TRAIL R2 expression on the human
hepatocyte cell line Huh7
Since human hepatocytes express the HIV chemokine co-
receptor CXCR4 on the surface, [15] and since HIV gp120
treatment of immune cells [6,16] increases TRAIL receptor
expression, we questioned whether soluble HIV gp120, that is
present during HIV infection, can signal through CXCR4 on the
surface of human hepatocytes and also increase TRAIL receptor
expression on the surface of the cell. When Huh7 cells, a human
hepatocyte cell line, were incubated with control protein, TRAIL
R1, R2, R3 or R4 expression was unchanged, yet pre-incubation
of Huh7 cells with HIV gp120 resulted in a significant increase in
TRAIL R2, but not R1, R3, nor R4 receptor expression as
determined by flow cytometry (Figure 2A). Similarly, Western blot
analysis confirms TRAIL R2 up-regulation after HIV gp120
incubation (Figure 2B). The effect of HIV gp120 on TRAIL R2
was abrogated by AMD3100, which binds CXCR4 and blocks
HIV gp120 binding without signaling through the receptor
(p,.005) [17–19] (Figure 2C). Consequently, the effect of HIV
gp120 on TRAIL R2 is mediated by interaction with CXCR4.
HIV gp120 renders Huh7 cells sensitive to TRAIL
Because individuals with HIV infection are more prone to liver
disease than non-infected individuals, and given that HIV gp120
makes immune cells sensitive to bystander TRAIL mediated
death, we sought to determine whether HIV gp120 also causes the
hepatocytes to become sensitive to TRAIL mediated apoptosis.
Human hepatocytes were incubated with HIV gp120 or control
protein for six hours and then stimulated with TRAIL. HIV gp120
alone induces hepatocyte death (p,.002), as previously described
[15]. TRAIL alone also caused minimal apoptosis. When TRAIL
was added after HIV gp120 incubation, there was a significant loss
of cell viability (p,.01) (Figure 3A), demonstrating that HIV
gp120 signals hepatocytes to become sensitive to TRAIL mediated
death. This acquired TRAIL sensitivity was blocked by AMD3100
pre-treatment of the cells (p,.01), confirming that the TRAIL
sensitivity was mediated by gp120/CXCR4 interaction.
HIV gp120 induced hepatocyte TRAIL sensitivity is
mediated by JNK II kinase but not p38 kinase or the
CXCR4 G-protein
HIV gp120 triggers a number of intracellular signals after binding
CXCR4. Gp120/CXCR4 T cell death is associated with p38
HIV and Liver Disease
PLoS ONE | www.plosone.org 2 February 2009 | Volume 4 | Issue 2 | e4623Figure 1. HIV IIIb makes Huh7 cells sensitive to TRAIL mediated apoptosis. Huh7 cells were pre-incubated or not with AMD3100 for one
hour followed by treatment with purified HIV IIIb or mock virus for six hours. Selective points were then treated with skTRAIL for twelve hours. Cells
were then fixed, permeabilized, and stained with fluorescently labeled anti-active caspase-3 antibodies and analyzed by flow cytometry.
Camptothesin (10 mM) was used as positive control for caspase-3 activation. (A) A single representative dot plot for each group is given. In each plot,
the percentage of cells positive for active caspase-3 is shown in the upper right quadrant. (B) Values are expressed as the mean6SD of three
independent experiments.
doi:10.1371/journal.pone.0004623.g001
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PLoS ONE | www.plosone.org 4 February 2009 | Volume 4 | Issue 2 | e4623Figure 3. HIV gp120 induces TRAIL sensitivity in Huh7 cells in a JNK dependent manner. (A) Huh7 cells were pre-incubated or not with
AMD3100 for one hour and then treated with HIV gp120 or BSA for six hours followed by treatment of skTRAIL. Cell viability was determined by
reduction of MTS by live cells. (B) Huh7 cells were pre-incubated with JNK II inhibitor, p38 inhibitor or the G-protein inhibitor, Pertussis toxin, for one
hour followed by treatment with HIV gp120 or control protein for six hours. Cell viability was determined by reduction of MTS in live cells. Values are
expressed as the mean6SD of three independent experiments from duplicate wells.
doi:10.1371/journal.pone.0004623.g003
Figure 2. HIV gp120 up-regulates TRAIL R2 expression in Huh7 cells. (A) Huh7 cells were treated with HIV gp120 or control protein for six
hours, stained with fluorescently conjugated antibodies specific for TRAIL receptors and analyzed by flow cytometry. BSA control protein is shown as
a dotted line, and HIV gp120 is shown as a solid line. A single representative histogram from three independent experiments is given for each group.
(B) Huh7 cells were treated with HIV gp120 for one, two, or three hours, lysed, and resolved on 15% SDS-PAGE, electrotransferred to PVDF membrane,
and probed for TRAIL R2. Densitometer readings are presented as the relative intensity of TRAIL R2 normalized to actin. The data represents the
mean6SD of three independent experiments. (C) Huh7 cells were pre-incubated or not with AMD3100 for one hour followed by treatment with HIV
gp120 or BSA and analyzed for TRAIL R2. Data of mean channel fluorescence represents the mean6SD of three independent experiments.
doi:10.1371/journal.pone.0004623.g002
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in a number of cell models [21,22]. SDF1a, the natural ligand of
CXCR4, induces chemotaxis through a G-protein dependent
mechanism. We therefore investigated the role of JNK II, p38, and
G-proteins on gp120 induced sensitivity to TRAIL. When Huh7 cells
were treated with HIV gp120, direct hepatocyte death was abrogated
by JNK II, p38, and G-protein inhibition, consistent with our prior
observations [15] (Figure 3B). However, TRAIL sensitivity was
blocked only when the cells were pre-incubated with JNK II kinase
inhibitor (p,.0005), but neither p38 inhibitor, nor the CXCR4
associated G-protein inhibitor, nor Pertussis toxin (Figure 3B). In
parallel experiments, Pertussis toxin blocked SDF1a induced T cell
chemotaxis, and the p38 inhibitor blocked HIV gp120 induced p38
phosphorylation in T cells (data not shown), confirming the activity of
these inhibitors. Consequently, JNKII kinase signaling isrequired for
HIV gp120 conferring TRAIL sensitivity. Unlike direct HIV gp120/
CXCR4 death signaling, acquired TRAIL sensitivity in hepatocytes
does not require p38.
HIV gp120 induced TRAIL R2 expression on hepatocytes
is mediated by JNK II kinase but neither JNK I nor p38
kinase
Given that HIV gp120 induced TRAIL sensitivity can be
abrogated by pre-incubating hepatocytes with JNK II kinase
inhibitors, we questioned whether the concomitant increase in
TRAIL R2 expression on hepatocytes is also mediated by the JNK
II kinase. Huh7 cells were transfected with siRNA for JNK I, JNK
II, p38 kinase, or scramble control, followed by treatment with
HIV gp120. After 18 hours of HIV gp120 treatment, the cells
were lysed and blotted for TRAIL R2. Figure 4A demonstrates
that JNK II inhibition by siRNA, but not p38 nor JNK I,
decreases TRAIL R2 expression to the level of BSA control.
Transfecting Huh7 cells with siRNA for JNK I, JNK II, or p38 did
not intrinsically alter TRAIL R2 levels (Figure 4B). Furthermore,
each siRNA inhibited the specific kinase without altering the levels
of JNK I, JNK II, or p38 respectively (Figure 4C). Therefore, JNK
II kinase is required for the HIV gp120 mediated increase in
TRAIL R2 levels in Huh7 cells, as well as the conferred TRAIL
sensitivity.
Discussion
Liver disease is a frequent cause of morbidity and mortality in
HIV infected individuals. Recently, the leading cause of death for
hospitalized HIV patients in the United States became liver
disease (MMWR) [23]. Multiple factors contribute to liver injury
during the course of HIV infection. Many patients are co-infected
with other viruses such as Hepatitis B, C, and D, as well as bacteria
and mycobacteria. In addition, highly active antiretroviral therapy
Figure 4. siRNA inhibition of JNK II inhibits gp120 induced TRAIL R2 upregulation. Huh7 cells were treated with either BSA or gp120 in the
presence or absence siRNA constructs for JNK I, JNK II, and p38; and analyzed for TRAIL R2 content (A). The results presented below are pooled TRAIL
R2 densitometry normalized to Actin. Parallel experiments demonstrate that siRNA for JNK I, JNK II, and p38 did not alter TRAIL R2 expression (B), and
these siRNA constructs were specific for the proteins against which they were directed (C).
doi:10.1371/journal.pone.0004623.g004
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result in varying degrees of liver injury. Although the causes of
HIV related liver disease are likely multifactorial, there are reports
of liver injury resulting from HIV infection alone [24,25].
Moreover, HIV RNA and the HIV antigen p24 have been
isolated from liver samples, presumably from immune cells in HIV
infected subjects, indicating that HIV virus and proteins are in
close proximity to hepatocytes during HIV infection [24,26].
During HIV infection, CD4
+ T cells are depleted by multiple
mechanisms; including HIV gp120 binding to the chemokine co-
receptor CXCR4 and resulting in resting CD4
+ T cell death
[27,28]. HIV gp120 kills non-immune cells as well, including
neurons and hepatocytes [14,15,29,30]. Gp120 ligation of
CXCR4 can also alter the sensitivity of immune cells to TRAIL
induced apoptosis by increasing TRAIL R2 expression on CD4
+ T
cells [16], or on neutrophils [6].
In the current report, we have extended the previous under-
standing of how HIV gp120 may contribute to hepatotoxicity. First,
as previously reported, gp120 ligation of CXCR4 expressed on
hepatocytes can cause hepatocyte death directly in a minority of
cells [15]. Second, in those cells which survive, CXCR4 signaling
results both in an up-regulation of TRAIL R2 expression and an
acquired sensitivity to TRAILinduceddeath.This latter effectlikely
has implications for other hepatic disease states associated with
TRAIL induced liver injury, and may explain why the course of
such diseases is accelerated in HIV infected patients.
Since human hepatocyte cell lines as well as freshly isolated
primary human hepatocytes express CXCR4 on the cell surface,
we tested the hypothesis that HIV gp120 could bind to CXCR4
and up-regulate TRAIL R2 and consequently induce TRAIL
sensitivity in human hepatocytes, thereby making the cells
vulnerable to apoptosis in settings of high TRAIL expression
(Figure 4). We show that consistent with prior reports, hepatocytes
are not sensitive to TRAIL apoptosis [31–33]. Moreover,
treatment with either HIV gp120 or whole virus induces an
acquired sensitivity of hepatocytes to TRAIL mediated killing.
Figure 5. Role of TRAIL in HIV/HCV co-infection. Schematic model of synergy between HIV gp120/CXCR4-induced TRAIL sensitivity and other
proapoptotic stimuli (e.g., HBV, HCV, Bile salts), causing hepatocyte death and consequent cirrhosis.
doi:10.1371/journal.pone.0004623.g005
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acids [35] and bile salts [36], or HCV [9,37]can increase TRAIL
expression, we propose a model (Figure 5) whereby HIV infection
alone induces TRAIL sensitivity in human hepatocytes which acts
synergistically with increased TRAIL expressed in other liver
disease states, thereby accelerating liver disease. In addition, the
enhanced TRAIL sensitivity of hepatocytes from HIV-infected
patients would be favored to undergo apoptosis following exposure
to TRAIL expressing immune cells. This is particularly relevant
given that TRAIL levels are elevated during HIV infection [38,39]
and there is increased TRAIL expression on hepatocytes during
infection with HCV [40], a common co-infection with HIV that
results in accelerated liver disease.
HIV gp120 death and signaling can be mediated through
several possible pathways. In immune cells, HIV gp120 binds
CXCR4 and causes a G-protein independent death that signals
via p38 [20]. In this hepatocyte model, HIV gp120 caused a small,
direct death of hepatocytes, as we have previously described, that
was p38 mediated, however, the HIV gp120/CXCR4 signaling
that induces hepatocyte TRAIL sensitivity appears to signal
differently. TRAIL sensitivity was independent of p38 and G-
protein signaling but required JNK kinase, can activate the
mitochondrial-dependent apoptosis pathway, and is involved in
TRAIL R2 signaling [41–43].
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